What is the next best step in evaluating a healthy 13-year-old with absent puberty, bone age of 11.5 years, and height 157 cm?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Evaluation of Absent Puberty in a 13-Year-Old

Measure serum LH, FSH, and testosterone (or estradiol if female) to differentiate between constitutional delay of growth and puberty versus hypogonadotropic hypogonadism.

Interpretation of Current Findings

The bone age of 11.5 years is delayed by approximately 1.5 years compared to chronological age of 13 years, which is consistent with either constitutional delay or pathologic hypogonadism 1, 2. This degree of bone age delay falls within the typical range seen in constitutional delay (mean delay of 2.4 ± 1 years), but does not definitively distinguish between benign and pathologic causes 3.

Height of 157 cm requires comparison to population-specific growth charts and mid-parental height to determine if this represents appropriate growth velocity or pathologic short stature 4.

Diagnostic Algorithm

First-Line Laboratory Testing

  • Obtain basal gonadotropins (LH and FSH) and sex steroids:
    • Low LH/FSH with low testosterone/estradiol indicates hypogonadotropic hypogonadism requiring further evaluation for pituitary or hypothalamic pathology 1
    • Normal or elevated LH/FSH with low sex steroids suggests primary gonadal failure 2
    • Low-normal gonadotropins with low sex steroids in the context of delayed bone age supports constitutional delay 3

Additional Initial Workup

  • Assess growth velocity over the preceding 6-12 months: Growth rate below 4.8 cm/year at this age suggests pathology beyond simple constitutional delay and warrants more aggressive investigation 3

  • Calculate mid-parental height: Significant deviation from genetic potential (>2 SD below corrected mid-parental height) increases likelihood of pathologic cause rather than constitutional delay 3

  • Evaluate for systemic illness: Screen for chronic disease (CBC, comprehensive metabolic panel, celiac serology, inflammatory markers) that could cause delayed puberty 1

Key Differentiating Features

Constitutional delay of growth and puberty is characterized by:

  • Family history of late puberty in parents or siblings 3
  • Proportionate delay in bone age relative to height age 1
  • Preserved growth velocity (typically >4 cm/year) 3
  • Otherwise normal physical examination and screening laboratories 2

Pathologic hypogonadism should be suspected when:

  • Bone age delay is disproportionate to clinical picture 2
  • Growth velocity is significantly impaired 3
  • Anosmia is present (suggesting Kallmann syndrome) 1
  • Other pituitary hormone deficiencies are detected 5

Critical Pitfall to Avoid

Do not assume constitutional delay without biochemical confirmation. Bone age delay alone does not distinguish between constitutional delay and hypogonadotropic hypogonadism 1, 2. Studies demonstrate that bone age at pubertal onset shows similar variability to chronological age in normal boys, and skeletal maturation does not directly predict pubertal timing 6. Therefore, hormonal assessment is mandatory before attributing delayed puberty to constitutional causes.

If Hypogonadotropic Hypogonadism is Confirmed

  • Obtain pituitary MRI to evaluate for structural lesions, including craniopharyngioma, pituitary adenoma, or other masses 5
  • Test additional pituitary axes (thyroid function, IGF-1, morning cortisol, prolactin) to identify multiple pituitary hormone deficiencies 5
  • Consider dynamic GH testing if growth velocity is impaired, as GH deficiency commonly coexists with gonadotropin deficiency 5

References

Research

Pubertal disorders and bone maturation.

Endocrinology and metabolism clinics of North America, 2012

Research

The use of bone age in clinical practice - part 1.

Hormone research in paediatrics, 2011

Guideline

Management of Bone Mineral Density Loss in Cushing Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Bone age and onset of puberty in normal boys.

Molecular and cellular endocrinology, 2006

Related Questions

What are the recommended guidelines for evaluating and managing cough in pregnancy?
Summarize biliary tract surgical procedures and other surgically relevant interventions such as endoscopic retrograde cholangiopancreatography (ERCP).
How should abdominal cramping in a postmenopausal woman be evaluated and managed?
What are the recommended management guidelines for cough in pregnancy?
What is the most common chromosomal abnormality in a 12‑week abortus?
Can you explain the evaluation and management plan for a patient with acute kidney injury of uncertain etiology, including the significance of a fractional excretion of sodium of 0.4%, the rationale for holding ibuprofen and lisinopril, adjusting gabapentin and vancomycin doses, and initiating intravenous fluid therapy?
Which laboratory tests should be monitored in patients with hyperthyroidism?
Can a non‑diabetic woman after laparoscopic sleeve gastrectomy, who previously had frequent post‑prandial hypoglycemia and took one week of semaglutide (Wegovy) 0.25 mg, experience a recurrence or worsening of hypoglycemia before starting diazoxide?
What long‑term regimen can minimize enlarged pores and fine wrinkles, incorporating microneedling (re‑needle) treatment?
Can you explain the significance of this patient's pre‑renal acute kidney injury with low fractional excretion of sodium, the modest improvement in elevated serum creatinine after intravenous fluids, new mild right ureteral dilation suggesting possible obstruction, significant candiduria with pyuria, the need to hold nephrotoxic drugs and adjust renally cleared medications, the initiation of fluconazole, and the pending MRI and urology evaluation?
In a 68-year-old male who is 6 ft 1.5 in tall, weighs 268 lb, has had a total hip replacement, resolved atrial fibrillation after two cardiac ablations with a Watchman left atrial appendage closure device, which glucagon‑like peptide‑1 (GLP‑1) receptor agonist or GLP‑1‑based combination would be most appropriate for weight loss?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.